Answers are grounded in this paper and cite their sources.
INTRODUCTION: Treatment-resistant schizophrenia (TRS) affects up to 30% of patients with schizophrenia and carries a substantial burden, yet clozapine, the only antipsychotic specifically indicated, is delayed by years because resistance is recognized retrospectively. Neuroimaging may provide objective biomarkers to shorten this delay. METHODS: We searched PubMed and Scopus to June 2026 following PRISMA guidelines. We included peer-reviewed neuroimaging studies investigating TRS, covering structural, functional, and metabolic modalities; studies not addressing TRS were excluded. Risk of bias was assessed using ROBINS-I for non-randomized studies and RoB 2 for randomized trials. Findings were synthesized qualitatively, without meta-analysis. RESULTS: Of 1502 identified records, 1179 were screened and 94 studies were included (44 structural, 18 functional, and 32 metabolic). TRS was characterized by extensive abnormalities in frontal cortical, limbic, and white matter pathways and, compared with treatment-responsive schizophrenia (nTRS), by the absence of striatal dopaminergic hyperactivity, alongside functional and metabolic alterations in frontal and cortico-subcortical circuits. Evidence concerning ultra-treatment-resistant schizophrenia (uTRS) remains scarce. CONCLUSIONS: Neuroimaging findings support a distributed cortico-subcortical phenotype and a non-dopaminergic, potentially glutamatergic pathophysiology in TRS. However, the evidence remains constrained by small, heterogeneous, predominantly cross-sectional studies, with uTRS still poorly investigated. PROTOCOL REGISTRATION: PROSPERO (CRD420261437825).
No takes yet. Share an insight, caveat, or question.
Bartolomeis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: